Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. FUJIFILM Holdings Corporation
  6. News
  7. Summary
    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FUJIFILM : BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases (Fujifilm)

05/18/2021 EDT

Cambridge, Mass., and Madison, Wis. [May 17, 2021] - BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc. a leading global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, LLC, a joint venture of FUJIFILM Cellular Dynamics (FCDI) and David Gamm, M.D., Ph.D., co-founder, focusing on developing cell therapies for patients with ocular diseases, today announced that they have entered into a strategic research and development (R&D) alliance.

As part of the alliance, the companies will combine their collective expertise to discover and develop off-the-shelf iPS cell therapies for ocular diseases. Under this agreement, BlueRock Therapeutics will have the option to exclusively license from both parties three (3) retinal cell therapy programs focused on dry age-related macular degeneration (AMD) and inherited retinal diseases (IRDs) containing human retinal pigment epithelial cells and photoreceptor cells, currently in pre-clinical development.

There is a strong strategic fit between BlueRock Therapeutics' mission to create an entirely new generation of cellular therapies, and FUJIFILM Cellular Dynamics and Opsis Therapeutics' shared mission to create best-in-class cell replacement therapies targeting degenerative retinal diseases.

'We believe deeply that authentic cells are the breakthrough approach needed to treat degenerative retinal diseases like AMD and IRDs,' states Emile Nuwaysir, Ph.D., President and CEO, BlueRock Therapeutics. 'This strategic alliance between BlueRock Therapeutics, Opsis Therapeutics, and FUJIFILM Cellular Dynamics will allow each party to do what they do best, and when combined with our deep expertise in ophthalmology at Bayer, we are well positioned to lead in this rapidly advancing field and potentially make a meaningful difference in millions of people's lives.'

'This alliance will leverage FUJIFILM Cellular Dynamics and Opsis Therapeutics' combined expertise in iPS cell technologies and understanding of retinal diseases, with BlueRock Therapeutics' experience in research and development of cell therapies, to provide next-generation ocular treatments,' says Takeshi Yamamoto, Chief Executive Officer, FUJIFILM Cellular Dynamics, Inc. 'We are excited to team with BlueRock Therapeutics to discover and develop cell therapies to reverse the progression of ocular diseases and restore vision for patients impacted by these conditions.'

'Millions of patients around the world today are suffering from permanent vision loss as a result of incurable ocular diseases,' states Nick Manusos, Chief Executive Officer, Opsis Therapeutics. 'Bringing together the expertise of our partners with Opsis Therapeutics' innovation in generating authentic iPS cell-derived human retinal cells, we have the potential to develop life-changing treatments for patients and their families.'

Under the terms of the agreement, FUJIFILM Cellular Dynamics and Opsis Therapeutics will receive an upfront payment of 30 million USD and up to 40 million USD R&D and part of manufacturing funding for the development of the three candidate programs. BlueRock Therapeutics will have the option to license the three programs on a program-by-program basis and will be responsible for development and commercialization of the licensed products. FUJIFILM Cellular Dynamics and BlueRock Therapeutics will share manufacturing responsibilities, with FUJIFILM Cellular Dynamics responsible for clinical supply and Parties sharing responsibility for commercial supply. Per the agreement, FUJIFILM Cellular Dynamics and Opsis Therapeutics will be eligible to receive payments upon achievement of certain development and commercial milestones, as well as tiered high single-digit/low double-digit royalty payments on a per-program basis.

Disclaimer

Fujifilm Holdings Corporation published this content on 18 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 June 2021 14:00:03 UTC.


© Publicnow 2021
All news about FUJIFILM HOLDINGS CORPORATION
07/19Charter Hall Long Wale Reit Enters into A Lease for Building C, 56 Edmondston..
CI
07/14FUJIFILM : Launches Virtual Hospital to Showcase that it's Comprehensive Healthc..
AQ
07/12FUJIFILM : finds new niches, record profits amid pandemic
AQ
07/09New Fujifilm CEO focuses on drug ingredients unit after Avigan stumbles
RE
07/01FUJIFILM : closing South Carolina plants; 400 to lose jobs
AQ
06/30FUJIFILM : Business Innovation Announces Management Changes (FUJIFILM Business I..
PU
06/24FUJIFILM : Expands Integrated Inkjet Solutions Business
AQ
06/24FUJIFILM : releases new features for its FUJIFILM 42K Printbar System; a configu..
AQ
06/24FUJIFILM : Enters Flexible Packaging Market with Launch of New Digital Inkjet Wa..
AQ
06/24FUJIFILM : to Launch X-BAR Powered by FUJIFILM Inkjet Technology, a Modular Inkj..
AQ
More news
Financials
Sales 2022 2 457 B 22 222 M 22 222 M
Net income 2022 148 B 1 341 M 1 341 M
Net Debt 2022 232 B 2 102 M 2 102 M
P/E ratio 2022 21,4x
Yield 2022 1,30%
Capitalization 3 152 B 28 517 M 28 507 M
EV / Sales 2022 1,38x
EV / Sales 2023 1,32x
Nbr of Employees 73 275
Free-Float 73,9%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 7 884,00 JPY
Average target price 8 471,43 JPY
Spread / Average Target 7,45%
EPS Revisions
Managers and Directors
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kunitaro Kitamura Independent Outside Director
Tatsuo Kawada Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
FUJIFILM HOLDINGS CORPORATION44.98%29 378
ABBOTT LABORATORIES8.00%200 283
MEDTRONIC PLC8.51%168 081
BECTON, DICKINSON AND COMPANY-0.35%70 145
HOYA CORPORATION3.33%50 251
ALIGN TECHNOLOGY, INC.17.50%48 667